Cargando…

Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical Trials

BACKGROUND/OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Interstitial lung disease (ILD) is an extra-articular manifestation of RA. We investigated incidence rates of ILD in patients with RA, receiving tofacitinib 5 or 10 mg twice daily, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Citera, Gustavo, Mysler, Eduardo, Madariaga, Hugo, Cardiel, Mario H., Castañeda, Oswaldo, Fischer, Aryeh, Richette, Pascal, Chartrand, Sandra, Park, Jin Kyun, Strengholt, Sander, Rivas, Jose L., Thorat, Amit V., Girard, Tanya, Kwok, Kenneth, Wang, Lisy, Ponce de Leon, Dario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612919/ https://www.ncbi.nlm.nih.gov/pubmed/32826657 http://dx.doi.org/10.1097/RHU.0000000000001552

Ejemplares similares

Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start
por: Ciurea, Adrian, et al.
Publicado: (2023)

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis
por: van Vollenhoven, Ronald, et al.
Publicado: (2019)

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
por: Wollenhaupt, Jürgen, et al.
Publicado: (2019)

Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis
por: Mortezavi, Mahta, et al.
Publicado: (2023)

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
por: Fleischmann, Roy, et al.
Publicado: (2023)

Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia‐Pacific region: Post‐hoc analyses of pooled clinical study data
por: Lee, Eun Bong, et al.
Publicado: (2019)

Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
por: Mueller, Ruediger B., et al.
Publicado: (2022)

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
por: Winthrop, K L, et al.
Publicado: (2016)

Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib
por: Curtis, Jeffrey R., et al.
Publicado: (2016)

Editorial: Drug Survival: Treatment of Rheumatic Diseases in the Biologic Era
por: Di Sanzo, Lorenzo, et al.
Publicado: (2022)

Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials
por: Landewé, Robert B. M., et al.
Publicado: (2016)

Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long‐term extension studies over 7 years
por: Chopra, Arvind, et al.
Publicado: (2020)

Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials
por: Tesser, John, et al.
Publicado: (2023)

Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials
por: Panaccione, Remo, et al.
Publicado: (2020)

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
por: Curtis, Jeffrey R, et al.
Publicado: (2016)

Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials
por: Panaccione, Remo, et al.
Publicado: (2020)

Tofacitinib for the Treatment of Severe Interstitial Lung Disease Related to Rheumatoid Arthritis
por: Vacchi, Caterina, et al.
Publicado: (2021)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
por: Dougados, Maxime, et al.
Publicado: (2022)

Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies
por: Fleischmann, Roy, et al.
Publicado: (2017)

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2016)

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
por: Li, Zhan-Guo, et al.
Publicado: (2018)

Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies
por: Ritchlin, Christopher T., et al.
Publicado: (2020)

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses
por: Strand, Vibeke, et al.
Publicado: (2018)

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
por: Winthrop, Kevin L., et al.
Publicado: (2017)

Tofacitinib
Publicado: (2012)

Tofacitinib with conventional synthetic disease‐modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient‐reported outcomes from a Phase 3 randomized controlled trial
por: Li, Zhanguo, et al.
Publicado: (2018)

Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
por: Takeuchi, Tsutomu, et al.
Publicado: (2021)

Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis
por: Kaine, Jeffrey, et al.
Publicado: (2020)

Erratum to Tofacitinib
Publicado: (2012)

Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice
por: Sendo, Sho, et al.
Publicado: (2019)

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
por: Orbai, Ana-Maria, et al.
Publicado: (2022)

Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib
por: Winthrop, Kevin L, et al.
Publicado: (2020)

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Interstitial lung disease in suggestive forms of connective tissue disease
por: Fischer, Aryeh
Publicado: (2013)

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years
por: Pope, Janet E., et al.
Publicado: (2019)

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
por: Mariette, Xavier, et al.
Publicado: (2018)

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment
por: Winthrop, Kevin L., et al.
Publicado: (2021)

Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects
por: Shin, Wonsuk, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fqp1vn37pd1p7h0h4dneqk7pjv